Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENGN enGene	$3.26 +9.0%	$3.65	$2.65 ▼ $11.00	$152.80M	-0.4	129,330 shs	167,253 shs
FDMT 4D Molecular Therapeutics	$4.08 +2.0%	$3.66	$2.24 ▼ $28.93	$185.30M	2.84	821,983 shs	199,893 shs
PBYI Puma Biotechnology	$3.31 -1.5%	$3.25	$2.23 ▼ $4.13	$166.76M	1.29	440,578 shs	208,950 shs
PRLD Prelude Therapeutics	$0.85 -2.4%	$0.91	$0.61 ▼ $6.80	$49.47M	1.25	282,647 shs	169,477 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENGN enGene	+9.03%	-0.91%	-23.11%	-31.37%	-59.75%
FDMT 4D Molecular Therapeutics	+2.00%	-0.24%	+16.91%	+14.61%	-81.45%
PBYI Puma Biotechnology	-1.49%	-2.65%	+2.48%	+5.08%	+11.82%
PRLD Prelude Therapeutics	-2.43%	-0.73%	-3.54%	+25.37%	-77.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENGN enGene	2.7907 of 5 stars	3.5	3.0	1.9	2.5	0.6
FDMT 4D Molecular Therapeutics	1.9913 of 5 stars	3.3	3.0	0.6	1.7	0.6
PBYI Puma Biotechnology	3.9894 of 5 stars	3.5	2.0	1.3	4.2	3.1
PRLD Prelude Therapeutics	3.2544 of 5 stars	3.5	2.0	0.0	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENGN enGene	3.00	Buy	$23.29	614.29% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	624.40% Upside
PBYI Puma Biotechnology	3.00	Buy	$7.00	111.48% Upside
PRLD Prelude Therapeutics	3.00	Buy	$4.50	426.44% Upside

Current Analyst Ratings Breakdown

Latest PRLD, FDMT, ENGN, and PBYI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
5/9/2025	FDMT 4D Molecular Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $38.00
5/5/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/29/2025	ENGN enGene	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$18.00 ➝ $18.00
4/29/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$4.00 ➝ $4.00
4/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/8/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)

(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENGN enGene	N/A	N/A	N/A	N/A	$4.45 per share	N/A
FDMT 4D Molecular Therapeutics	$40K	4,725.66	N/A	N/A	$11.05 per share	0.37
PBYI Puma Biotechnology	$230.50M	0.71	$0.84 per share	3.94	$1.88 per share	1.76
PRLD Prelude Therapeutics	$7M	6.89	N/A	N/A	$2.39 per share	0.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENGN enGene	-$55.14M	-$1.65	N/A	N/A	N/A	N/A	-32.60%	-28.26%	N/A
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/6/2025 (Estimated)
PBYI Puma Biotechnology	$30.28M	$0.77	4.30	8.71	N/A	16.37%	49.35%	18.25%	7/30/2025 (Estimated)
PRLD Prelude Therapeutics	-$127.17M	-$1.69	N/A	N/A	N/A	N/A	-89.18%	-69.26%	8/11/2025 (Estimated)

Latest PRLD, FDMT, ENGN, and PBYI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/10/2025	Q2 2025	ENGN enGene	-$0.4768	-$0.51	-$0.0332	-$0.51	N/A	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
5/6/2025	Q1 2025	PRLD Prelude Therapeutics	-$0.47	-$0.42	+$0.05	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENGN enGene	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENGN enGene	0.09	12.66	12.66
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
PBYI Puma Biotechnology	0.11	1.53	1.43
PRLD Prelude Therapeutics	N/A	5.18	5.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENGN enGene	64.16%
FDMT 4D Molecular Therapeutics	99.27%
PBYI Puma Biotechnology	61.29%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
ENGN enGene	10.40%
FDMT 4D Molecular Therapeutics	9.60%
PBYI Puma Biotechnology	23.30%
PRLD Prelude Therapeutics	63.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENGN enGene	31	51.10 million	45.79 million	N/A
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
PBYI Puma Biotechnology	200	49.63 million	38.07 million	Optionable
PRLD Prelude Therapeutics	120	56.46 million	20.38 million	Optionable

PRLD, FDMT, ENGN, and PBYI Headlines

Recent News About These Companies

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

5 hours ago | finance.yahoo.com

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

5 hours ago | finance.yahoo.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLC

June 8, 2025 | marketbeat.com

Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025

June 3, 2025 | msn.com

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

June 2, 2025 | globenewswire.com

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges

May 28, 2025 | investing.com

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

May 15, 2025 | fiercebiotech.comF

Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs

May 10, 2025 | msn.com

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025

May 4, 2025 | msn.com

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 1, 2025 | globenewswire.com

Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies

April 30, 2025 | msn.com

Prelude Announces Presentations at 2025 AACR Annual Meeting

April 25, 2025 | globenewswire.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know

April 10, 2025 | zacks.com

Prelude Therapeutics Founder Acquires 28% More Stock

March 29, 2025 | finance.yahoo.com

Prelude Therapeutics CEO buys $467K in common stock

March 28, 2025 | markets.businessinsider.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $69,000.00 in Stock

March 28, 2025 | insidertrades.com

Prelude Therapeutics stock surges on insider buying

March 27, 2025 | investing.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 Shares

March 15, 2025 | insidertrades.com

Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements

March 14, 2025 | msn.com

Analysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)

March 12, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD, FDMT, ENGN, and PBYI Company Descriptions

enGene NASDAQ:ENGN

$3.26 +0.27 (+9.03%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$3.28 +0.02 (+0.58%)

As of 06/25/2025 07:55 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

4D Molecular Therapeutics NASDAQ:FDMT

$4.08 +0.08 (+2.00%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$4.08 +0.00 (+0.12%)

As of 06/25/2025 06:07 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Puma Biotechnology NASDAQ:PBYI

$3.31 -0.05 (-1.49%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$3.38 +0.07 (+2.11%)

As of 06/25/2025 04:38 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Prelude Therapeutics NASDAQ:PRLD

$0.85 -0.02 (-2.43%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$0.86 +0.00 (+0.02%)

As of 06/25/2025 06:23 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time